Oral paclitaxel with encequidar improves overall survival and progression-free survival in breast cancer

2. The OS was 22.7 months as opposed to 16.5 months, and the PFS was 8.4 months as opposed to 7.4 months. 55% of oPac + E and 53% of IVpac adverse events were grade 3-4.

3. In comparison to IVpac, oPac + E had higher rates of nausea, vomiting, diarrhea, and neutropenic complications, especially in patients with elevated liver enzymes.

4. However, it had lower incidence and severity of neuropathy (2% v 15% > grade 2) and alopecia (49% v 62% all grades).

5. Treatment was a factor in 3% of on-study fatalities and 0% of on-study deaths (8% oPac + E vs. 9% IVpac).

In conclusion, oPac + E group increased the confirmed tumor response better than IVpac. The Authors also found that in oPac + E group, neuropathy was less common while neutropenic infections were more common in patients with increased liver enzyme levels at baseline. 

Reference:

Rugo, H. S., Umanzor, G. A., Barrios, F. J., Vasallo, R. H., Chivalan, M. A., Bejarano, S., Ramírez, J. R., Fein, L., Kowalyszyn, R. D., Kramer, E. D., Wang, H., Kwan, M.-F. R., & Cutler, D. L. (2022). Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. In Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.21.02953